stockportfolio.pro
Stocks / ARGX vs BSX
ARGX vs BSX
argenx SE and Boston Scientific Corporation side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| argenx SE (ARGX) | Boston Scientific Corporation (BSX) | |
|---|---|---|
| Market cap | $55.7B | $69.5B |
| Revenue (latest FY) | $4.15B | $20.07B |
| Net income (latest FY) | $1.29B | $2.90B |
| Revenue growth (5y CAGR) | 116.2% | 15.2% |
| Net margin | 31.1% | 14.4% |
| Return on equity | 17.6% | 12.0% |
| P/E ratio | 39.6 | 19.6 |
| Dividend yield | — | — |
| Profitable years (of last 10) | 2 | 9 |
| Positive free cash flow | Yes | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open ARGX — free Open BSX — freeFrequently asked questions
Which is bigger, ARGX or BSX?
Boston Scientific Corporation is larger by market capitalization — $69.5B versus $55.7B.
Which grows faster, ARGX or BSX?
Over the last five fiscal years, argenx SE grew revenue faster — 116.2%/yr versus 15.2%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.